Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Bluebird bio Inc (NASDAQ: BLUE) violated securities laws in connection with certain financial statements.
The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Bluebird bio Inc (NASDAQ: BLUE) concerning whether a series of statements by Bluebird bio Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On December 1, 2018, the Company issued a press release informing investors that it had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).”
On December 3, 2018, an article published by Seeking Alpha revealed “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.”
Following this news, NASDAQ: BLUE fell $6.39 per share, or 5.2%, to close at $116.50 on December 3, 2018.
Based in Cambridge, Massachusetts, and founded in 1992 Bluebird bio Inc focuses on developing transformative gene therapies for severe genetic diseases and cancer.
If you purchased shares of Bluebird bio Inc (NASDAQ: BLUE) on or before December 1, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.
Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.
Thieler Law Corp
2534 State Street - Suite 406,
San Diego, CA 92101
by
email: mail@thielerlaw.com
or
telephone at +1 (619) 377 - 4324
or
visit our website http://www.thielerlaw.com/
or
Facsimile: +1 (619) 785 – 3185
